Molecular background of chemoresistance in pancreatic cancer

In Vivo

Volumn 21, Issue 2, 2007, Pages 339-347

  Zalatnai, Attila ^a   Molnár, József ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Chemoresistance; Gemcitabine; P glycoprotein; Pancreatic cancer; Review

Indexed keywords

1,3 DIMETHYL 1,3 BIS(4 FLUOROPHENYL) 1,3 BIS(3 MORPHOLINOPROPYL)DISILOXANE; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; CYCLIN D1; CYTOSTATIC AGENT; DOCETAXEL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LUNG RESISTANCE PROTEIN; MORPHOLINE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; NUCLEOSIDE TRANSPORTER; ORGANOSILICON DERIVATIVE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BNIP3; SILA 409; UNCLASSIFIED DRUG; VINCRISTINE; ABC TRANSPORTER; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; CYTOSTASIS; DRUG ELIMINATION; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HYPOXIA; METASTASIS; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STROMA CELL; SURVIVAL RATE; SURVIVAL TIME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; PANCREAS TUMOR; PHENOTYPE; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, NEOPLASM; HUMANS; PANCREATIC NEOPLASMS; PHENOTYPE;

EID: 34047216068     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Kindler HL: Front-line therapy of advanced pancreatic cancer. Semin Oncol 32(Suppl. 9): S33-36, 2005.
2. El-Rayes BF and Philip PA: A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol 1: 430-434, 2003.
3. Durand RE: Intermittent blood flow in solid tumors - an under-appreciated source of 'drug resistance'. Cancer Metast Rev 20: 57-61, 2001.
4. Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T and Yamazaki Y: Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 92: 1788-1797, 2001.
5. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H and Miyake M: Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79: 1553-1563, 1999.
6. Karademir S, Sokmen S, Terzi C, Sagol O, Ozer E, Astarcioglu H, Coker A and Astarcioglu I: Tumor angiogenesis as a prognostic predictor in pancreatic cancer. J Hepatobiliary Pancreat Surg 7: 489-495, 2000.
7. Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A and Post S: Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 28: 31-39, 2000.
8. Ozer E, Ozkal S, Karademir S, Sagol O, Sokmen S, Coker A, Kupelioglu A and Astarcioglu I: Angiogenesis and p53 and H-ras mutations in pancreatic ductal adenocarcinoma. Anal Quant Cytol Histol 21: 473-476, 1999.
9. Mirecka J, Libura J, Libura M, Koprowski M, Nowak D, Kedra B and Popiela T: Morphological parameters of the angiogenic response in pancreatic ductal adenocarcinoma - correlation with histological grading and clinical data. Folia Histochem Cytobiol 39: 335-340, 2001.
10. Ohshima T, Yamaguchi T, Ishihara T, Yoshikawa M, Kobayashi A, Sakaue N, Baba T, Yamada S and Saisho H: Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor. Pancreas 28: 335-343, 2004.
11. Linder S, Blasjo M, von Rosen A, Parrado C, Falkmer UG and Falkmer S: Pattern of distribution and prognostic value of angiogenesis in pancreatic duct carcinoma: a semiquantitative immunohistochemical study of 45 patients. Pancreas 22: 240-247, 2001.
12. Jia L, Zhang MH, Yuan SZ and Huang WG: Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol 11: 447-450, 2005.
13. de Gramont A and Van Cutsem E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69(Suppl 3): 46-56, 2005.
14. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM and Vokes EE: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040, 2005.
15. Podgorska M, Kocbuch K and Pawelczyk T: Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 52: 749-758, 2005.
16. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR and Cass CE: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357, 1998.
17. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M: Nucleoside transporter profiles in human pancretic cancer cells: role of hCNT1 in 2′,2″-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 15: 5000-5008, 2003.
18. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R and Mackey JR: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956-6961, 2004.
19. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F and Danesi R: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66: 3928-3935, 2006.
20. Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5: 19-33, 2002.
21. Obata T, Endo Y, Murata D, Sakamoto K and Sasaki T: The molecular targets of antitumor 2′-deoxycytidine analogues. Curr Drug Targets 4: 305-313, 2003.
22. Sebastiani V, Ricci F, Rubio-Viquiera B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D and Iacobuzio-Dohahue CA: Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12: 2492-2497, 2006.
23. Ruiz van Haperen VW, Veerman G, Braakhuis BJ, Vermorken JB, Boven E, Leyva A and Peters GJ: Deoxycytidine kinase and deoxycytidine deaminase activities in human tumor xenografts. Eur J Cancer 29A: 2132-2137, 1993.
24. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B and Peters GJ: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65: 9510-9516, 2005.
25. Maehara S, Tanaka S, Shimada M, Shirabe K, Saito Y, Takahashi K and Maehara Y: Selenoprotein P as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer 112: 184-189, 2004.
26. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR and Schäfer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251, 2003.
27. Li L, Aggarwal BB, Shishodia S, Abbruzzese J and Kurzrock R: Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101: 2351-2362, 2004.
28. Sharma J, Srinivasan R, Majumdar S, Mir S, Radotra BD and Wig JD: Bcl-XL protein levels determine apoptotic index in pancreatic carcinoma. Pancreas 30: 337-342, 2005.
29. Dong M, Zhou JP, Zhang H, Guo KJ, Tian Yl and Dong YT: Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J Gastroenterol 11: 2744-2747. 2005.
30. Sun CY, Wang BL, Hu CQ, Peng RY, Gao YB, Gu QY and Wang DW: Expression of the bcl-2 gene and its significance in human pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 1: 306-308, 2002.
31. Xu ZW, Friess H, Büchler MW and Solioz M: Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 49: 504-510, 2002.
32. Giroux V, Malicet C, Barthet M, Gironella M, Archange C, Dagorn JC, Vasseur S and Iovanna JL: p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res 12: 235-241, 2006.
33. Müerköster SS, Lust J, Arlt A, Hasler R, Witt M, Sebens T, Schreiber S, Fölsch UR and Schäfer H: Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene 25: 3973-3981, 2006.
34. Li Y, Jian Z, Xia K, Li X, Lv X, Pei H, Chen Z and Li J: XIAP is related to chemoresistance and inhibition of its expression by RNA interference sensitizes pancreatic carcinoma cells to chemotherapeutics. Pancreas 32: 288-296, 2006.
35. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA and Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24: 4421-4432, 2005.
36. Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, Matsuno S and Lemoine NR: Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11: 3094-3101, 2005.
37. Yokoi K and Fidler IJ: Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 10: 2299-2306, 2004.
38. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A and Shimosegawa T: Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92: 271-278, 2001.
39. Westphal S and Kalthoff H: Apoptosis: targets in pancreatic cancer. Molecular Cancer 2: 6, 2003.
40. Nakai Y, Otsuka M, Hoshida Y, Tada M, Komatsu Y, Kawabe T and Omata M: Identifying genes with differential expression in gemcitabme-resistant pancreatic cancer cells using comprehensive transcriptome analysis. Oncol Rep 14: 1263-1267, 2005.
41. Suwa H, Ohshio G, Arao S, Imamura T, Yamaki K, Manabe T, Imamura M, Hiai H and Fukumoto M: Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Jpn J Cancer Res 87: 641-649, 1996.
42. Sagol O, Yavuzsen T, Oztop I, Ulukus C, Ylmaz U, Alakavuklar M, Karademir S, Obuz F, Astarcioglu H and Astarcioglu I: The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma. Pancreas 30: 343-348, 2005.
43. Lu Z, Kleeff J, Shrikhande S, Zimmermann T, Korc M, Friess H and Büchler MW: Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 21: 240-247, 2000.
44. Miller DW, Fontain M, Kolar C and Lawson T: The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 107: 301-306, 1996.
45. Zhao YP, Zhang LY, Liao Q, Guo JC, Chen G and Li JY: Detection of multidrug resistant gene 1 in pancreatic cancer. Hepatobiliary Pancreat Dis Int 3: 307-310, 2004.
46. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM and Pastan I: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
47. Zalatnai A and Molnár J: Effect of SILA-409, a new organosilicon multidrug resistance modifier on human pancreatic cancer xenografts. In Vivo 20: 137-140, 2006.
48. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K and Okumura K: Cytotoxic effects of 27 anticancer drugs in HeLA and MDR1-overexpressing derivate cell lines. Biol Pharm Bull 25: 771-778, 2002.
49. Liu B, Staren ED, Iwamura T, Appert HE and Howard JM: Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 99: 179-186, 2001.
50. Liu B, Staren E, Iwamura T, Appert H and Howard J: Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2. World J Gastroenterol 7: 143-148, 2001.
51. Yusuf RZ, Duan Z, Lamendola DE, Penson RT and Seiden MV: Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1-19, 2003.
52. Smith NF, Figg WD and Sparreboom A: Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20: 163-175, 2006.
53. König J, Hartel M, Nies AT, Martignoni ME, Guo J, Büchler MW, Friess H and Keppler D: Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115: 359-367, 2005.
54. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, Bian JS, Huang M, Zhu YZ, Xiong W, Li X and Zhou S: Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 22: 1837-1853, 2005.
55. Verovski VN, Van den Berge DL, Delvaeye MM, Scheper RJ, De Neve WJ and Storme GA: Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer 73: 596-602, 1996.
56. Zalatnai A: Molecular aspects of stromal - parenchymal interactions in malignant neoplasms. Current Mol Med 6: 685-693, 2006.
57. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, Sebens T, Klöppel G, Kalthoff H, Fölsch UR and Schäfer H: Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1β. Cancer Res 64: 1331-1337, 2004.
58. Arlt A, Vorndamm J, Müerköster S, Yu H, Schmidt WE, Fölsch UR and Schäfer H: Autocrine production of interleukin-1-β confers constitutive NFκB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62: 910-916, 2002.
59. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H and Tashiro S: Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28: 38-44, 2004.
60. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW and Whang EE: A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 64: 3987-3993, 2004.
61. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW and Whang EE: RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res 11: 3433-3438, 2005.
62. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N and Beger HG: Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57: 1634-1637, 1997.
63. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG and Korc M: Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 55: 363-369, 1998.
64. Kornmann M, Arber N and Korc M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 101: 344-352, 1998.
65. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV and Korc M: Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59: 3505-3511, 1999.
66. Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH and Liao JD: Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 11: 6075-6086, 2005.
67. Kornmann M, Ishiwata T, Arber N, Beger HG and Korc M: Increased cyclin D1 expression in chronic pancreatitis. Pancreas 17: 158-162, 1998.
68. Müerköster S, Arlt A, Sipos B, Witt M, Grossmann M, Klöppel G, Kalthoff H, Fölsch UR and Schäfer H: Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 65: 1316-1324, 2005.
69. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, Gallick GE and Ellis LM: Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 93: 233-241, 2005.
70. Volm M: Multidrug resistance and its reversal. Anticancer Res 18: 2905-2917, 1998.
71. Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165, 2003.
72. Wang RB, Kuo CL, Lien LL and Lien EJ: Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28: 203-228, 2003.
73. Nieth C, Priebsch A, Stege A and Lage H: Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 545: 144-150, 2003.
74. Kamiya D, Uchihata Y, Ichikawa E, Kato K and Umezawa K: Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I. Bioorg Med Chem Lett 15: 1111-1114, 2005.
75. 2-terminal kinase. Cancer Res 66: 445-452, 2006.
76. Molnár J, Mucsi I, Nacsa J, Hevér A, Gyémánt N, Ugocsai K, Hegyes P, Kiessig S, Gaál D, Lage H and Varga A: New silicon compounds as resistance modifiers against multidrug-resistant cancer cells. Anticancer Res 24: 865-872, 2004.
77. Gorunova L, Hoglund M, Andren-Sandberg A, Dawiskiba S, Jin Y, Mitelman F and Johansson B: Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 23: 81-99, 1998.
78. Grutzmann R, Boriss H, Ammerpohl O, Lüttges J, Kalthoff H, Schackert HK, Klöppel G, Saeger HD and Pilarsky C: Metaanalysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24: 5079-5088, 2005.
79. Tönnies H and Lage H: Chromosomal imbalances associated with drug resistance and thermoresistance in human pancreatic carcinoma cells. Eur J Cell Biol 83: 591-601, 2004.